211 related articles for article (PubMed ID: 23100498)
1. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
6. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
Palomino JC; Martin A
Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
[TBL] [Abstract][Full Text] [Related]
9. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
Xu HB; Jiang RH; Li L; Xiao HP
Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
[TBL] [Abstract][Full Text] [Related]
12. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
[TBL] [Abstract][Full Text] [Related]
13. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
14. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
15. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
16. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
17. Management of multidrug resistant tuberculosis.
Daley CL; Caminero JA
Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
[TBL] [Abstract][Full Text] [Related]
18. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Schön T; Simonsson US; Bruchfeld J; Larsson M; Juréen P; Sturegård E; Giske CG; Ängeby K
Antimicrob Agents Chemother; 2014 Dec; 58(12):7557-9. PubMed ID: 25246405
[TBL] [Abstract][Full Text] [Related]
19. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
[TBL] [Abstract][Full Text] [Related]
20. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Xu HB; Jiang RH; Xiao HP
Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
